

**PB 72 of 2024**

**National Health (Efficient Funding of Chemotherapy) Special Arrangement Amendment (July Update) Instrument 2024**

*National Health Act 1953*

I, NIKOLAI TSYGANOV, Assistant Secretary, Pricing and PBS Policy Branch, Technology Assessment and Access Division, Department of Health and Aged Care, delegate of the Minister for Health and Aged Care, make this Instrument under subsection 100(2) of the *National Health Act 1953*.

Dated 27 June 2024

**NIKOLAI TSYGANOV**

Assistant Secretary

Pricing and PBS Policy Branch

Technology Assessment and Access Division

Contents

1 Name 1

2 Commencement 1

3 Authority 1

4 Schedules 1

Schedule 1—Amendments 2

National Health (Efficient Funding of Chemotherapy) Special Arrangement 2024
(PB 31 of 2024) 2

1. Name
2. This instrument is the *National Health (Efficient Funding of Chemotherapy) Special Arrangement Amendment (July Update) Instrument 2024*
3. This instrument may also be cited as PB 72 of 2024.
4. Commencement
5. Each provision of this instrument specified in column 1 of the table commences, or is taken to have commenced, in accordance with column 2 of the table. Any other statement in column 2 has effect according to its terms.

| Commencement information |
| --- |
| Column 1 | Column 2 | Column 3 |
| Provisions | Commencement | Date/Details |
| 1. *The whole of this instrument* | *1 July 2024* | *1 July 2024* |

Note: This table relates only to the provisions of this instrument as originally made. It will not be amended to deal with any later amendments of this instrument.

1. Any information in column 3 of the table is not part of this instrument. Information may be inserted in this column, or information in it may be edited, in any published version of this instrument.
2. Authority

This instrument is made under subsection 100(2) of the *National Health Act 1953*.

1. Schedules

Each instrument that is specified in a Schedule to this instrument is amended or repealed as set out in the applicable items in the Schedule concerned, and any other item in a Schedule to this instrument has effect according to its terms.

Schedule 1—Amendments

*National Health (Efficient Funding of Chemotherapy) Special Arrangement 2024 (PB 31 of 2024)*

1. **Part 1, Section 5, Definition for *diluent fee***

*omit:* **$5.77** *substitute:* **$5.95**

1. Part 1, Section 5, Definition for *dispensing fee*

*omit:* **$8.37** *substitute:* **$8.67**

1. **Part 1, Section 5, Definition for *distribution fee***

*omit:* **$29.15** *substitute:* **$30.05**

1. **Part 1, Section 5, Definition for *preparation fee***

*omit:* **$88.62** *substitute:* **$90.13**

1. **Schedule 1, Part 1, entry for Pembrolizumab**

*omit from the column headed “Circumstances”:* **C14028**

1. **Schedule 1, Part 2, entry for Cetuximab**

*substitute:*

|  |  |  |  |
| --- | --- | --- | --- |
| Cetuximab | P4788 | 550 mg | 5 |
|  | P4785 P4794 | 880 mg  | 0 |
|  | P4908 P12045 P12483 | 1100 mg | 0 |
|  | P12016 P12470 | 1100 mg | 11 |
|  | P4912 | 1100 mg | 18 |

1. **Schedule 1, Part 2, entry for Pembrolizumab *[Maximum Amount: 400 mg; Number of Repeats: 6]***

*omit from the column headed “Purposes”:* **P14028**

1. **Schedule 2, entry for Ondansetron in the form Tablet 4 mg (as hydrochloride dihydrate)**

*substitute:*

|  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | Tablet 4 mg (as hydrochloride dihydrate) | Oral | APO-Ondansetron | C5778 |  | 4 | 0 | V5778 |
|  |  |  | APX-Ondansetron | C5778 |  | 4 | 0 | V5778 |
|  |  |  | Ondansetron-DRLA | C5778 |  | 4 | 0 | V5778 |
|  |  |  | Ondansetron Mylan Tablets | C5778 |  | 4 | 0 | V5778 |
|  |  |  | Ondansetron SZ | C5778 |  | 4 | 0 | V5778 |
|  |  |  | Ondansetron Tablets Viatris | C5778 |  | 4 | 0 | V5778 |
|  |  |  | Zofran | C5778 |  | 4 | 0 | V5778 |
|  |  |  | Zotren 4 | C5778 |  | 4 | 0 | V5778 |

1. **Schedule 2, entry for Ondansetron in the form Tablet 8 mg (as hydrochloride dihydrate)**

*substitute:*

|  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | Tablet 8 mg (as hydrochloride dihydrate) | Oral | APO-Ondansetron | C5778 |  | 4 | 0 | V5778 |
|  |  |  | APX-Ondansetron | C5778 |  | 4 | 0 | V5778 |
|  |  |  | Ondansetron-DRLA | C5778 |  | 4 | 0 | V5778 |
|  |  |  | Ondansetron Mylan Tablets | C5778 |  | 4 | 0 | V5778 |
|  |  |  | Ondansetron SZ | C5778 |  | 4 | 0 | V5778 |
|  |  |  | Ondansetron Tablets Viatris | C5778 |  | 4 | 0 | V5778 |
|  |  |  | Zofran | C5778 |  | 4 | 0 | V5778 |
|  |  |  | Zotren 8 | C5778 |  | 4 | 0 | V5778 |

1. **Schedule 3, Part 1, omit entry for Circumstances Code “C14028”**